Conference Proceedings

Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II)

C LaGanke, J De Seze, MS Freedman, M Habek, RMM Hupperts, V Limmroth, RAL Macdonell, KW Selmaj, DH Margolin, K Thangavelu, E Havrdova


University of Melbourne Researchers


Awarded by Ministry of Education of Czech Republic

Funding Acknowledgements

Sanofi Genzyme and Bayer Healthcare Pharmaceuticals.MSF: Honoraria or consulting fees (Actelion, Bayer Healthcare, Biogen, Canada Innovation, Chugai, EMD Canada, Hoffman-La Roche, Merck Serono, Novartis, Sanofi Aventis, Sanofi Genzyme, and Teva); serving on advisory boards, board of directors or other similar group (Actelion, Bayer Healthcare, Biogen, Hoffman-La Roche, Merck Serono, Novartis, Opexa, and Sanofi Aventis); and participation in speaker's bureau (Sanofi Genzyme).RMMH: Research grants, speaker's fees and honoraria for advisory boards (Biogen, Merck, Novartis, Sanofi Genzyme, and Teva).KS: Consulting and/or speaking fees (Biogen Idec, Merck, Novartis, Roche, Sanofi Genzyme, and Synthon).EH: Honoraria and grant support (Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi Genzyme, and Teva), and support from Ministry of Education of Czech Republic, project PRVOUK -P26/LF1/4).